Shaolin Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Shaolin Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,010	Closed	-$13K	–	837
2022 Q4	$13K	Hold	200,010	–	–	﹤0.01%	642
2022 Q3	$12K	Hold	200,010	–	–	﹤0.01%	811
2022 Q2	$18K	Buy	200,010 +99,977	+100%	+$20.7K	﹤0.01%	859
2022 Q1	$24K	Buy	100,033 +46,589	+87%	+$14.9K	﹤0.01%	873
2021 Q4	$35K	Buy	+53,444	New	+$37.1K	﹤0.01%	719

Shaolin Capital Management's BIOTW Position: Q1 2023 in Review

Shaolin Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 200,010 shares — an estimated $13K sold.

Shaolin Capital Management first reported a position in BIOTW in Q4 2021 and held it in 5 quarters. The position peaked at $35K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Shaolin Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Shaolin Capital Management sold 200,010 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $13K.
Shaolin Capital Management first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 5 quarters.
Shaolin Capital Management's Biotech Acquisition Company Warrant position peaked at $35K in Q4 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Shaolin Capital Management's 13F filing for Q1 2023, filed 15 May 2023.